SCHEMBL5173

SCHEMBL5173

[CH2]C(C)C1CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22534005 1.00
SCHEMBL6244090 0.87 TRPA1 (0.31)
SCHEMBL5482 0.86
SCHEMBL5242 0.86
SCHEMBL23628575 0.83
SCHEMBL20510547 0.83 SHBG (0.43)
SCHEMBL4326 0.83 SHBG (0.43)
SCHEMBL5144 0.83 SHBG (0.43)
SCHEMBL5277 0.83
SCHEMBL4228253 0.83 SHBG (0.43)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 806 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116354894-A Substituted piperazine compound and application thereof in medicines 广东东阳光药业有限公司 2023-06-30 CN claimed
CN-116354862-A Substituted azacyclic compounds and application thereof in medicines 广东东阳光药业有限公司 2023-06-30 CN claimed
US-20220220102-A1 D3 RECEPTOR AGONIST COMPOUNDS; METHODS OF PREPARATION; INTERMEDIATES THEREOF; AND METHODS OF USE THEREOF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2022-07-14 US claimed
EP-3953350-A1 D3 RECEPTOR AGONIST COMPOUNDS; METHODS OF PREPARATION; INTERMEDIATES THEREOF; AND METHODS OF USE THEREOF The United States of America, as Represented by The Department of Health and Human Services (US) 2022-02-16 EP claimed
US-10973832-B2 Muscarinic M1 receptor agonists HEPTARES THERAPEUTICS LIMITED (GB) 2021-04-13 US claimed
WO-2020210785-A1 D3 RECEPTOR AGONIST COMPOUNDS; METHODS OF PREPARATION; INTERMEDIATES THEREOF; AND METHODS OF USE THEREOF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2020-10-15 WO claimed
US-20200253982-A1 MUSCARINIC M1 RECEPTOR AGONISTS NXERA PHARMA UK LIMITED (GB) 2020-08-13 US claimed
CN-106831541-B Muscarinic M 1 receptor agonists 赫普泰雅治疗有限公司 2019-09-06 CN claimed
US-9907805-B2 Muscarinic M1 receptor agonists HEPTARES THERAPEUTICS LIMITED (GB) 2018-03-06 US claimed
EP-3089980-B1 SERINE/THREONINE KINASE INHIBITORS ARRAY BIOPHARMA INC (US) 2018-01-31 EP claimed
EP-1551403-B1 5-SUBSTITUTED 2H-PYRAZONE-3-CARBOXYLIC ACID DERIVATIVES AS ANTILIPOLYTIC AGENTS FOR THE TREATMENT OF METABOLIC-RELATED DISORDERS SUCH AS DYSLIPIDEMIA ARENA PHARM INC (US) 2009-04-29 EP claimed
EP-1560834-B1 NEW TRICYCLIC DERIVATIVES AS LTD4 ANTAGONISTS ALMIRALL LAB (ES) 2008-06-25 EP claimed
CN-100379742-C novel tricyclic derivatives as LTD4 antagonists ALMIRALL PRODESFARMA SA (ES) 2008-04-09 CN claimed
US-20060116363-A1 Tricyclic derivatives as ltd4 antagonists LABORATORIOS ALMIRALL, S.A. (ES) 2006-06-01 US claimed
CN-1735618-A New tricyclic derivatives as LTD4 antagonists ALMIRALL PRODESFARMA SA (ES) 2006-02-15 CN claimed
CN-1720046-A 5-substituted 2H-pyrazole-3-carboxylic acid derivatives as antilipolytic agents for the treatment of metabolic-related diseases such as dyslipidemia ARENA PHARM INC (US) 2006-01-11 CN claimed
EP-1551403-A1 5-SUBSTITUTED 2H-PYRAZONE-3-CARBOXYLIC ACID DERIVATIVES AS ANTILIPOLYTIC AGENTS FOR THE TREATMENT OF METABOLIC-RELATED DISORDERS SUCH AS DYSLIPIDEMIA Arena Pharmaceuticals, Inc. (US) 2005-07-13 EP claimed
WO-2004032928-A1 5-SUBSTITUTED 2H-PYRAZONE-3-CARBOXYLIC ACID DERIVATIVES AS ANTILIPOLYTIC AGENTS FOR THE TREATMENT OF METABOLIC-RELATED DISORDERS SUCH AS DYSLIPIDEMIA ARENA PHARMACEUTICALS, INC. (US) 2004-04-22 WO claimed
US-5674891-A ANALGESICS WITH SIDE EFFECT REDUCTION THE PROCTER & GAMBLE COMPANY (US) 1997-10-07 US claimed
EP-0718280-A2 Derivatives of beta-aminopropionic acid with a fungicidal activity ISAGRO RICERCA S.r.l. (IT) 1996-06-26 EP claimed